Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies.

Its diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell), conjugated immunostimulants for the treatment of cancer (ALT-702), and intranasal vaccines (NasoVAXTM and NasoShieldTM).

Founded in 1997, the company is headquartered in the USA.